Loading viewer...
investor_presentation
Format: PDF investor_presentation
Biocon Limited presents its Q3 FY23 financial and operational results as a global biopharmaceutical leader. The company operates with revenue of ₹8,397 Cr (~$1.1 bn) and serves over 120 countries with innovative, affordable therapies across 7 manufacturing facilities.
investor_presentation
23 Pages
investor_presentation
38 Pages
Emera
Rand Capital Investor Presentation — May 2020
investor_presentationinvestor_presentation
14 Pages
Rand Capital Corporation